BlancheMavromatisMD

Oncology • Cumberland, MD

Medical Oncology UPMC Western Maryland

Join to view full profile

Dr. Mavromatis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mavromatis' full profile

Already have an account?

Office
12500 Willowbrook Rd
Cumberland, MD 21502
Phone+1 240-964-1400

Fax+1 240-964-8688

Education & Training

Georgetown University HospitalFellowship, Medical Oncology, 1997 - 2000
MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 1998 - 1999
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1994 - 1997
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1994

Certifications & Licensure

MD State Medical License 2007 - 2025
DC State Medical License 1999 - 2008
VA State Medical License 1996 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry Start of enrollment: 2015 Nov 01
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis.
Amit A Kulkarni, Cassandra Hennessy, Grace Wilson, Vidhyalakshmi Ramesh, Clara Hwang
Clinical Lung Cancer. 2024-07-01
The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study.
Cecilia A Castellano, Tianyi Sun, Deepak Ravindranathan, Clara Hwang, Nino Balanchivadze
Cancer. 2024-06-15
22 citations
Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COV...
Toni K Choueiri, Chris Labaki, Ziad Bakouny, Chih-Yuan Hsu, Andrew L Schmidt
Lancet Regional Health. Americas. 2023-03-01